Image pharmaphorum Editor Disease Spotlight Adaptations and positivity are key to living in the light wi... It took 30 years for Krister Inde to find out the visual impairment that developed when he was 19 was caused by the rare genetic condition LHON. News CEO of UK drugs regulator quits, as Brexit nears The CEO of the UK’s medicine regulator has announced he will leave his post in September next year. News FDA approves Sobi's Gamifant for rare, fatal childhood disea... The FDA has approved Sobi's Gamifant, a treatment for primary hemophagocytic lymphohistiocytosis (HLH). News Roche pulls extended use application for kidney cancer drug Roche has withdrawn an application to the European Medicines Agency (EMA) for an expanded use for its immunotherapy drug, Tecentriq. Load more results
Disease Spotlight Adaptations and positivity are key to living in the light wi... It took 30 years for Krister Inde to find out the visual impairment that developed when he was 19 was caused by the rare genetic condition LHON.
News CEO of UK drugs regulator quits, as Brexit nears The CEO of the UK’s medicine regulator has announced he will leave his post in September next year.
News FDA approves Sobi's Gamifant for rare, fatal childhood disea... The FDA has approved Sobi's Gamifant, a treatment for primary hemophagocytic lymphohistiocytosis (HLH).
News Roche pulls extended use application for kidney cancer drug Roche has withdrawn an application to the European Medicines Agency (EMA) for an expanded use for its immunotherapy drug, Tecentriq.
News FDA starts review of Regeneron's drug for rare disease FOP Can Regeneron's drug for ultra-rare bone disease FOP pick up the baton from Ipsen's Sohonos, whose growth has stalled?
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
